American Society for Colposcopy and Cervical Pathology.
J Low Genit Tract Dis. 2000 Apr;4(2):99-105.
: Editor's Note: This guideline was first published in The Colposcopist in January 1996 and reflected the peer-reviewed literature available on the management of ASCUS at that time. The decision to republish this guideline in The Journal of Lower Genital Tract Disease, to accompany guidelines on the management of low-grade squamous intraepithelial lesion (LGSIL) and benign cellular changes (BCC) was made to complete the set of guidelines in the Journal pertaining to management of the cytology screening system. (See also previous guidelines on Management Issues Related to the Quality of the Smear, Management of Atypical Glandular Cells of Undetermined Significance (AGUS), and the Abnormal Pap Follow-up System.) Our original intention was to update the ASCUS guideline for this publication in the expectation that the data from the enrollment phase of the National Cancer Institute's ASCUS LGSIL Triage Study (ALTS) would be available to provide relevant evidence-based recommendations. The unavailability of this data at this time has ensured a later update of the ASCUS guideline. However, an accumulating body of new literature, particularly on the clinical utility of HPV testing with Hybrid Capture II (Digene Corp., Gaithersburg, MD), will be incorporated within the next year with the enrollment ALTS data in a new ASCUS guideline. Until that time, the guideline presented here remains the recommendation of the ASCCP, based on the review of the literature at that time, and on the collective experience and knowledge of the ASCCP Practice Committee and the Board of Directors.The cost analysis in this guideline is based upon a set of cost assumptions which will vary from setting to setting. This analysis is intended to serve as a reference for average costs in a fee-for-service setting. The individual practitioner will need to analyze cost differentials for his/her own setting.This guideline reflects emerging clinical and scientific advances as of February 1996, and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed.
本指南最初于 1996 年 1 月发表在《阴道镜》杂志上，反映了当时可获得的有关 ASCUS 管理的同行评议文献。决定在《下生殖道疾病杂志》上重新发表本指南，以配合有关低级别鳞状上皮内病变（LSIL）和良性细胞变化（BCC）管理的指南，是为了完成该杂志中有关细胞学筛查系统管理的指南集。（另请参见以前有关涂片质量管理问题的指南、非典型腺细胞意义不明（AGUS）的管理和异常巴氏随访系统）。我们的初衷是为本次出版更新 ASCUS 指南，希望能获得美国国立癌症研究所的 ASCUS-LSIL 分流研究（ALTS）入组阶段的数据，以便提供相关的循证建议。由于目前无法获得这些数据，因此 ASCUS 指南的更新将推迟。然而，在接下来的一年中，将结合登记 ALTS 数据，将越来越多的新文献，特别是关于 HPV 检测与杂交捕获二代（Digene 公司，马里兰州盖瑟斯堡）的临床应用的文献，纳入新的 ASCUS 指南。在此之前，本指南中提出的建议仍然是 ASCCP 的建议，是基于当时的文献综述，以及 ASCCP 实践委员会和董事会的集体经验和知识。本指南中的成本分析基于一套成本假设，这些假设将因环境而异。该分析旨在为服务收费环境中的平均成本提供参考。个别从业者需要分析其自身环境的成本差异。本指南反映了截至 1996 年 2 月的临床和科学新进展，并可能会发生变化。该信息不应被解释为规定了必须遵循的独家治疗或程序。
